Македонски Фармацевтски Билтен

Macedonian Pharmaceutical Bulletin

волумен **68** (додаток 1) 2022 / volume **68** (Suppl 1) 2022

Македонско фармацевтско друштво, ул. Маршал Тито 13б/8, Скопје, Македонија
Macedonian Pharmaceutical Association, Marshal Tito 13b/8, Skopje Macedonia

It is our great pleasure to present this Supplement Issue on "*Macedonian Pharmaceutical Bulletin*" to the scientific and professional community. This supplement includes the short communications accepted for the *Seventh Congress of Pharmacy in North Macedonia with International participation 2022*, which was held in Ohrid, October 5-9, 2022.

The main theme of the Congress was "Modern trends in Pharmacy: opportunities and challenges" A broad spectrum of topics within the pharmaceutical sciences and practice carefully selected for this special occasion in order to build up a highly interesting and comprehensive program were covered. The contributions submitted to the Congress included 6 plenary lectures, 69 section lectures, and more that 200 posters. This Congress, followed the excellent international tradition, was attended by more than 1000 domestic and foreign participants. We received more than 287 short paper submissions from more than 15 countries. These numbers show that our Congress was aiming for the highest scientific standards, and that it can be considered a well-established venue for researchers in the broad fields of Pharmaceutical sciences and practice.

Sincere thanks to the hosts of the Seventh Congress of Pharmacy in North Macedonia with International participation, Macedonian Pharmaceutical Association and Faculty of Pharmacy, Ss Cyril and Methodius University in Skopje for their vision and commitments.

We would like to thank the companies that showed interest in supporting our efforts during the organization. We acknowledge the sponsoring companies: the platinum sponsor AD ALKALOID, Skopje, the golden sponsors: PLIVA-TEVA, EUROFARM, REPLEK and KRKA, the silver sponsor HEMOFARM and the bronze sponsors: GALENIKA, SEPTIMA and SALVEO,

We would also like to thank our members of the Scientific Committee for their volunteer time and dedication to the critical peer review process. We also wish to thank all the members of the Organizing Committee, whose work and commitment was invaluable.

On behalf of the Advisory and Scientific Committees, we would like to especially thank all internationally prominent researchers, whose work was supposed to be an essential part of the Congress. The interest in publishing their short communications in this issue of the Macedonian Pharmaceutical Bulletin is of a crucial importance for reinforcing the overall quality and standards of the bulletin. They give the state of the art of the recent advances in the field of pharmacy research.

The pharmaceutical sciences continue to grow as dynamic scientific interdisciplinary fields. We believe that published short communications will be an excellent source of scientific material in the fast evolving fields in Pharmaceutical sciences and practice.

Chair of the Scientific Committee

Prof. Marija Glavas Dodov

Chair of the Organizing Committee

Prof. Rumenka Petkovska

Your hosts
Macedonian Pharmaceutical Association
and
Faculty of Pharmacy, Ss Cyril and Methodius University in Skopje

Organizing Committee

Rumenka Petkovska, Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy/Chair
Aleksandra Kapedanovska Nestorovska, Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy/ Secretary
Dushko Shalabalija, Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy
Liljana Anastasova, Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy
Blagoj Achevski, Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy
Biljana Taneva, Alkaloid AD Skopje
Snezana Petrovska, Alkaloid AD Skopje

Advisory Board

Aleksandar Dimovski – North Macedonia, Aneta Dimitrovska – North Macedonia, Atila Hinchal – Turkey, Biljana Bauer – North Macedonia, Ilkay Orhan - Turkey, Irena Mlinarič-Raščan – Slovenia, Jelena Filipovic-Grcic – Croatia, Kristina Mladenovska – North Macedonia, Katerina Goracinova – North Macedonia, Lidija Petrusevska Tozi – North Macedonia, Lilian Azzopardi – Malta, Ljubica Suturkova – North Macedonia, Renata Slaveska Raicki – North Macedonia, Rumenka Petkovska – North Macedonia, Slađana Šobajić – Serbia, Suzana Trajkovic Jolevska – North Macedonia, Svetlana Kulevanova – North Macedonia, Tatjana Kadifkova Panovska – North Macedonia, Vasia Bankova – Bulgaria, Zoran Kavrakovski – North Macedonia, Zoran Sterjev – North Macedonia

Scientific Committee

Marija Glavas Dodov / Chair
Maja Simonoska Crcarevska / Secretary

Aleksandra Grozdanova – North Macedonia
Aleksandra Kapedanovska Nestorovska – North Macedonia
Ales Mrhar – Slovenia
Ana Poceva Panovska – North Macedonia
Andreas Zimmer – Austria
Antonio Makris – Greece
Arijana Meštrović – Croatia
Beti Djurdjic – Montenegro
Betul Arica Yegin-Turkey
Brigita Djordjevic – Serbia
César Viseras Iborra – Spain
Dea Baricevik – Slovenia
Dimitar Efremov – Italy
Dinko Vitezic – Croatia
Edina Vranic – Bosnia and Herzegovina
Ela Hoti – Albania
Giangiacomo Beretta – Italy
Gjose Stefkov – North Macedonia
Hari Polenakovik – USA
Henning Blume – Germany
Ivan Stankovic – Serbia
Ivana Cvetkovikj Karanfilova – North Macedonia
Jan Tytgat – Belgium
Janina Lulek – Poland
Jasmina Tonic Ribarska – North Macedonia
Jelena Acevska – North Macedonia
Johanes Novak – Austria
Katerina Ancevska Netkovska – North Macedonia
Katerina Brezovska – North Macedonia
Kevin O'Donnell – Ireland
Liljana Anastasova – North Macedonia
Luciano Saso – Italy
Maija Dambrova – Latvia
Margarida Caramona – Portugal
Maria Halabalaki – Greece
Marija Hiljadnikova Bajro – North Macedonia
Marija Karapandzova – North Macedonia
Milen I. Georgiev – Bulgaria
Mirko Trajkovski – Switzerland
Nada Majkic-Singh – Serbia
Nadica Matevska Geskovska – North Macedonia
Natalija Nakov – North Macedonia
Nikola Geskovski – North Macedonia
Rok Dreu – Slovenia
Rubin Zareski – North Macedonia
Sanda Vladimir-Knezevic – Croatia
Sema Calis – Turkey
Slavica Ražić – Serbia
Sokol Abazi – Albania
Suela Kellici – Albania
Tanja Petreska – North Macedonia
Vilma Papajani Toska – Albania
Zorica Naumovska – North Macedonia

This issue of *Macedonian Pharmaceutical Bulletin* contains short papers accepted by the Scientific Committee for the presentation at the 7th Congress of Pharmacy in Macedonia with international participation 2022.

The authors are fully responsible for the contents of their short papers.

All reviewers that were involved in the short papers revision process are sincerely acknowledged.

Macedonian pharmaceutical bulletin, 68 (Suppl 1) 223 - 224 (2022)
Online ISSN 1857 - 8969
*DOI:*10.33320/maced.pharm.bull.2022.68.03.106
Short communication

Applicability of *Expert System for Drug Development* as a tool for co-processed excipients formulation development

Ivana Vasiljević*, Erna Turković, Svetlana Ibrić, Dragana Vasiljević, Jelena Parojčić

Department of Pharmaceutical Technology and Cosmetology,
University of Belgrade – Faculty of Pharmacy, Vojvode Stepe 450, 11221 Belgrade, Serbia

Introduction

Expert System for Drug Development, i.e. SeDeM Expert System (Span. *Sistema Experto para DEsarrollo de Medicamentos*) represents a method intended for evaluation of powder properties affecting processability, particularly compression behavior (Pérez et al., 2006). Additionally, it is recognized as useful formulation tool, since it provides identification of impaired powder properties and facilitates formulation development suitable for direct compression, based on mathematical equations. Relevant parameters described in SeDeM Expert System are divided into 5 groups and denoted as "incidence factors", namely: *Density*, *Compression*, *Flowability*, *Particle Size* and *Stability* (Aguilar-Díaz et al., 2014).

The aim of this work was to investigate mannitol- and lactose-based co-processed excipients, based on SeDeM Expert System methodology, and assess its suitability for compressible formulation development.

Materials and methods

Six co-processed excipients were used in the study: i) lactose-based: CombiLac® (Meggle Pharma), MicroceLac® 100 (Meggle Pharma) and StarLac® (Meggle Pharma), and ii) mannitol-based: Disintequik™ ODT (Kerry), Ludiflash® (BASF), Pharmaburst 500® (SPI Pharma), as well as two model drugs: caffeine and ibuprofen.

Investigated powders were characterized in terms of relevant SeDeM Expert System incidence factors: i) *Density*: bulk and tapped density, ii) *Compression*: inter-particle porosity (calculated from bulk and tapped density values), Carr index, tensile strength of compacts obtained at 500 kg compression load (calculated from compact hardness, diameter and thickness), iii) *Flowability*: Hausner ratio, angle of repose, iv) *Particle Size:* fines fraction, i.e. fraction of particles smaller than 45 μm, and v) *Stability*: moisture content. Each parameter was mathematically transformed into corresponding radius parameter, ranging from 0 (not acceptable) to 10 (perfect for compression), according to SeDeM Expert System.

Comprehensive excipients' and model drugs' characterization was used for powder comparison and excipients' assessment for compressible formulation development, according to Equation (1):

$$EC = 100 - \frac{ER-5}{ER-MR} \cdot 100 \quad (1)$$

where EC represents concentration of excipient to be added, ER represents relevant excipient radius parameter, MR is relevant model drug radius parameter and 5 represents radius parameter limit value, i.e. minimal acceptable parameter value (Aguilar-Díaz et al., 2014).

The obtained excipient-model drug blends were also characterized based on SeDeM Expert System methodology. Additionally, compacts (6 mm diameter) were prepared and investigated in terms of disintegration time, according to European Pharmacopoeia.

Results and discussion

Co-processed excipients' characterization

The investigated co-processed excipients exhibited comparable and, generally, favorable characteristics. All excipients exhibited acceptable density-related parameters (*Density* incidence factor values 4.30-6.59), apart from Pharmaburst 500, with somewhat lower bulk and tapped density (0.38 and 0.48 g/mL, respectively). In terms of *Compression,* mannitol-based excipients were favorable to lactose-based excipients (*Compression* incidence factor values 4.36-5.48 and 5.53-6.38, for mannitol- and lactose-

*ivanav@pharmacy.bg.ac.rs

based excipients, respectively). Tensile strength values of the prepared compacts were generally higher than 1 MPa, considered as the acceptable value.

The most notable difference among excipients was evident regarding parameters describing powder flowability. Lactose-based excipients exhibited favorable flowability-related parameters (*Flowability* incidence factor values from 7.90 to 8.40) in comparison to mannitol-based excipients (*Flowability* incidence factor values 2.45-6.14). The obtained *Particle Size* and *Stability* incidence factors were high (higher than 7), indicating low fines fraction and low moisture content, which is suitable for direct compression.

Model drugs' characterization

Both investigated model drugs exhibited acceptable compression-, particle size- and stability-related parameters, while *Flowability* incidence factor values were low (0.41 and 1.50, for caffeine and ibuprofen, respectively). The obtained Hausner ratio values were 1.47 and 1.35, for caffeine and ibuprofen, respectively, while angle of repose was around 45%, classifying the investigated model drugs into powders with very poor flow, according to Pharmacopoeial criteria. Additionally, ibuprofen *Density* incidence factor was 3.97, which is lower than 5, suggested as acceptable in SeDeM Expert System. Caffeine showed somewhat advantageous *Density*, *Compression* and *Flowability* incidence parameters in comparison to ibuprofen.

Formulation development based on SeDeM Expert System

It was determined that the suitable excipients should exhibit high *Flowability,* and *Density* and *Flowability* parameters, to improve the characteristics of caffeine and ibuprofen, respectively. In order to obtain compressible formulations, caffeine was mixed with CombiLac® (57.4%), while StarLac® (50.7%) was selected for formulation with ibuprofen. Prepared powder blends exhibited improved density- and flowability-related parameters in comparison to model drug characteristics. Powder blend *Compression* incidence factors decreased in comparison to model drugs', which is contributed to high flowability of lactose-based excipients and less tendency to sticking. The prepared compacts exhibited high tensile strength (3.10 and 1.13 MPa, for compacts with caffeine and ibuprofen, respectively) and disintegrated very quickly, in less than 2 minutes (disintegration time 116 s and 16 s, for compacts with caffeine and ibuprofen, respectively). Generally, the obtained powder blends' parameters were more similar to excipients, particularly the mixture with StarLac®, indicating high dilution capacity. SeDeM Expert System enhanced the appropriate excipient selection and addition, based on model drug limitations, and enabled compressible formulation development. In spite of mathematical equation, it was not possible to predict the exact parameter values, which is related to complex behavior of powder mixtures, excipient dilution capacity and percolation threshold.

Conclusion

The investigated co-processed excipients exhibited comparable characteristics. Lactose-based excipients were favorable in terms of flowability, while mannitol-based excipients were more suitable for compression.

SeDeM Expert System was found as useful aid for powder assessment and comparison. It facilitated the appropriate excipient selection and addition, for diminishing impaired model drug characteristics, based on mathematical equation. In the case of caffeine, 57.4% of CombiLac® was added, while StarLac® (50.7%) was mixed with ibuprofen. The prepared mixtures exhibited improved density- and flowability-related parameters and the obtained compacts showed high tensile strength (higher than 1 MPa) and short disintegration time (less than 2 minutes). However, SeDeM Expert System simplifies the excipient characteristics, neglects dilution capacity and percolation threshold, which should be taken into account for better understanding of excipient and model drug mixtures' properties.

Acknowledgement

This research was funded by the Ministry of Education, Science and Technological Development, Republic of Serbia through Grant Agreement with University of Belgrade-Faculty of Pharmacy No: 451-03-68/2022-14/200161.

References

Aguilar-Díaz, J.E., García-Montoya, E., Pérez-Lozano, P., Suñé-Negre, J.M., Minarro, M., Ticó, J.R., 2014. SeDeM expert system a new innovator tool to develop pharmaceutical forms. Drug Dev. Ind. Pharm. 40(2), 222-236. https://doi.org/10.3109/03639045.2012.756007

Pérez, P., Suñé-Negre, J.M., Miñarro, M., Roig, M., Fuster, R., García-Montoya, E., Hernández, C., Ruhí, R., Ticó, J.R., 2006. A new expert system (SeDeM Diagram) for control batch powder formulation and preformulation drug products. Eur. J. Pharm. Biopharm. 64(3), 351-359. https://doi.org/10.1016/j.ejpb.2006.06.008